We respond to new research into fertility drugs and breast cancer risk
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, commented on new research into the relationship between fertility drugs and breast cancer risk.
21 Jun 2021
We respond to POLQ inhibitors identified as a new class of targeted drugs for cancers with BRCA mutations
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, responded to POLQ inhibitors identified as a new class of targeted drugs for cancers with BRCA mutations.
17 Jun 2021
We respond to new figures from Cancer Research UK showing thousands fewer breast cancer patients started treatment in the last year in England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to new figures from Cancer Research UK showing thousands fewer breast cancer patients started treatment in the last year.
15 Jun 2021
We respond to a new clinical trial into olaparib use for women with high risk HER2 negative primary breast cancer with altered BRCA genes
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, commented that this study could help achieve a targeted treatment for HER2 negative primary breast cancer.
08 Jun 2021
We respond to government funding announcement for early career researchers supported by charities
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said investment from the government is urgently needed to enable medical research charities to continue to support young scientists.
08 Jun 2021
We respond to the announcement of more than £25m being invested in diagnostic equipment for NHS Wales
Mia Rosenblatt, Associate Director of Evidence, Policy and Influencing at Breast Cancer Now, commented on the announcement of more than £25m being invested in diagnostic equipment for NHS Wales.
03 Jun 2021
We respond to NHS Breast Screening Programme Statistics for Scotland 2017/18 to 2019/20
Mia Rosenblatt, Associate Director of Evidence, Policy and Influencing at Breast Cancer Now, commented on NHS Breast Screening Programme Statistics for Scotland 2017/2018 to 2019/2020.
01 Jun 2021
We respond to NHS England breast cancer waiting times: March 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, commented on NHS England breast cancer waiting times during March 2021.
13 May 2021
We respond to the Clinical Radiology UK Workforce Census 2020 Report from The Royal College of Radiologists
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, responded to the latest Clinical Radiology UK Workforce Census 2020 Report.
28 Apr 2021
We welcome the approval of trastuzumab deruxtecan for use on the Cancer Drugs Fund
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said it's fantastic that breast cancer drug trastuzumab deruxtecan (Enhertu) has been approved for use on the NHS in England.
20 Apr 2021
We respond to NHS England breast cancer waiting times: February 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, commented on NHS England breast cancer waiting times for February 2021.
15 Apr 2021
We welcome introduction of new treatment method for HER2 positive breast cancer by NHS England
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said that approval of Phesgo in England will benefit thousands of women with HER2 positive breast cancer.
04 Apr 2021